Powered by lexis nexis

Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results

Mar 01, 2017 - PR Newswire

 Kindred Biosciences, Inc. (NASDAQ: KIN) (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2016.  

"We are very pleased with the progress of Mirataz(TM) and Zimeta(TM), including the recently announced approval of the efficacy technical section for Mirataz," stated Richard Chin, M.D., President and CEO of KindredBio. "We are looking forward to the transiti...